KPTI Live signals | Maximize Profits with Getagraph.com

BUY 112640 min ago

@ $1.418

Issued: 14 Feb 2024 @ 15:43

Return: -23.84%

Previous signal: Feb 13 - 12:41

Previous signal: Sell

Return: 12.54 %

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 16:00):

Stats
Today's Volume	959 021
Average Volume	1.78M
Market Cap	125.78M
EPS	$0 ( 2024-02-29 )
Next earnings date	( $-0.330 ) 2024-05-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.860
ATR14	$0.00300 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-22	Rangwala Reshma	Sell	6 789	Common Stock
2024-04-04	Paulson Richard A.	Sell	3 563	Common Stock
2024-03-05	Paulson Richard A.	Sell	3 573	Common Stock
2024-02-29	Rangwala Reshma	Sell	15 667	Common
2024-03-01	Rangwala Reshma	Sell	5 969	Common

INSIDER POWER
69.87
Last 99 transactions
Buy: 2 857 011 \| Sell: 554 783

Volume Correlation

Long: -0.30 (neutral)

Short: -0.84 (strong negative)

Signal:(11.114) Be Aware. Possible trading coming up! (swing)

Karyopharm Therapeutics Correlation

10 Most Positive Correlations
RMRM	0.914
GAINL	0.87

10 Most Negative Correlations
BRAG	-0.833
EM	-0.806
AVTE	-0.804
ARCE	-0.803

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Karyopharm Therapeutics Correlation - Currency/Commodity

-0.49
( neutral )

-0.51
( weak negative )

0.00
( neutral )

-0.30
( neutral )

0.52
( weak )

Karyopharm Therapeutics Financials

Annual	2023
Revenue:	$146.03M
Gross Profit:	$140.56M (96.25 %)
EPS:	$-1.250

FY	2023
Revenue:	$146.03M
Gross Profit:	$140.56M (96.25 %)
EPS:	$-1.250

FY	2022
Revenue:	$157.07M
Gross Profit:	$151.86M (96.68 %)
EPS:	$-2.02

FY	2021
Revenue:	$209.82M
Gross Profit:	$206.42M (98.38 %)
EPS:	$-1.650

Financial Reports:

No articles found.

Karyopharm Therapeutics

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.